{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:34:13Z","timestamp":1772120053105,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-025-01127-9","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:26:54Z","timestamp":1762162014000},"page":"2073-2084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial"],"prefix":"10.1007","volume":"48","author":[{"given":"Ting","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiujie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"3","key":"1127_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74(3), 229\u2013263 (2024). https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"1127_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"B. Han, R. Zheng, H. Zeng, S. Wang, K. Sun, R. Chen et al., Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4(1), 47\u201353 (2024). https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006","journal-title":"J. Natl. Cancer Cent."},{"issue":"1","key":"1127_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-019-0372-x","volume":"39","author":"K Gao","year":"2019","unstructured":"K. Gao, J. Wu, National trend of gastric cancer mortality in China (2003\u20132015): a population-based study. Cancer Commun. 39(1), 1\u20135 (2019). https:\/\/doi.org\/10.1186\/s40880-019-0372-x","journal-title":"Cancer Commun."},{"key":"1127_CR4","doi-asserted-by":"publisher","first-page":"11014","DOI":"10.7189\/jogh.12.11014","volume":"12","author":"H Li","year":"2022","unstructured":"H. Li, H. Zhang, H. Zhang, Y. Wang, X. Wang, H. Hou, Survival of gastric cancer in China from 2000 to 2022: a nationwide systematic review of hospital-based studies. J. Glob Health. 12, 11014 (2022). https:\/\/doi.org\/10.7189\/jogh.12.11014","journal-title":"J. Glob Health"},{"issue":"1","key":"1127_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jso.23940","volume":"112","author":"VE Strong","year":"2015","unstructured":"V.E. Strong, A. Wu, L.V. Selby, M. Gonen, M. Hsu, K.Y. Song et al., Differences in gastric cancer survival between the U.S. And China. J. Surg. Oncol. 112(1), 31 (2015). https:\/\/doi.org\/10.1002\/jso.23940","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"1127_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"F Wang","year":"2023","unstructured":"F. Wang, X. Zhang, L. Tang, Q. Wu, M. Cai, Y. Li et al., The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun. 44(1), 127\u2013172 (2023). https:\/\/doi.org\/10.1002\/cac2.12516","journal-title":"Cancer Commun."},{"issue":"5","key":"1127_CR7","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s13402-024-00951-9","volume":"47","author":"D Shi","year":"2024","unstructured":"D. Shi, Z. Yang, Y. Cai, H. Li, L. Lin, D. Wu et al., Research advances in the molecular classification of gastric cancer. Cell. Oncol. 47(5), 1523\u20131536 (2024). https:\/\/doi.org\/10.1007\/s13402-024-00951-9","journal-title":"Cell. Oncol."},{"issue":"9742","key":"1127_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Y.-J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376(9742), 687\u2013697 (2010). https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"issue":"10294","key":"1127_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Y.Y. Janjigian, K. Shitara, M. Moehler, M. Garrido, P. Salman, L. Shen et al., First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 398(10294), 27\u201340 (2021). https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"issue":"11","key":"1127_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"S.Y. Rha, D.-Y. Oh, P. Ya\u00f1ez, Y. Bai, M.-H. Ryu, J. Lee et al., Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24(11), 1181\u20131195 (2023). https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6","journal-title":"Lancet Oncol."},{"issue":"10389","key":"1127_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"K. Shitara, F. Lordick, Y.-J. Bang, P. Enzinger, D. Ilson, M.A. Shah et al., Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 401(10389), 1655\u20131668 (2023). https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7","journal-title":"Lancet"},{"issue":"35","key":"1127_CR12","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"S. Hironaka, S. Ueda, H. Yasui, T. Nishina, M. Tsuda, T. Tsumura et al., Randomized, open-label, phase III study comparing Irinotecan with Paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J. Clin. Oncol. 31(35), 4438\u20134444 (2013). https:\/\/doi.org\/10.1200\/JCO.2012.48.5805","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"1127_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HER Ford","year":"2014","unstructured":"H.E.R. Ford, A. Marshall, J.A. Bridgewater, T. Janowitz, F.Y. Coxon, J. Wadsley et al., Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 15(1), 78\u201386 (2014). https:\/\/doi.org\/10.1016\/S1470-2045(13)70549-7","journal-title":"Lancet Oncol."},{"issue":"9","key":"1127_CR14","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.3390\/ijms20092106","volume":"20","author":"G Sammarco","year":"2019","unstructured":"G. Sammarco, G. Varricchi, V. Ferraro, M. Ammendola, M. De Fazio, D.F. Altomare et al., Mast cells, angiogenesis and lymphangiogenesis in human gastric cancer. Int. J. Mol. Sci. 20(9), 2106 (2019). https:\/\/doi.org\/10.3390\/ijms20092106","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"1127_CR15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"H. Wilke, K. Muro, E. Van Cutsem, S.-C. Oh, G. Bodoky, Y. Shimada et al., Ramucirumab plus Paclitaxel versus placebo plus Paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15(11), 1224\u20131235 (2014). https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6","journal-title":"Lancet Oncol."},{"issue":"12","key":"1127_CR16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(21)00313-7","volume":"6","author":"R-H Xu","year":"2021","unstructured":"R.-H. Xu, Y. Zhang, H. Pan, J. Feng, T. Zhang, T. Liu et al., Efficacy and safety of weekly Paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol. Hepatol. 6(12), 1015\u20131024 (2021). https:\/\/doi.org\/10.1016\/S2468-1253(21)00313-7","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"8","key":"1127_CR17","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1038\/s41591-024-02989-6","volume":"30","author":"F Wang","year":"2024","unstructured":"F. Wang, L. Shen, W. Guo, T. Liu, J. Li, S. Qin et al., Fruquintinib plus Paclitaxel versus placebo plus Paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial. Nat. Med. 30(8), 2189\u20132198 (2024). https:\/\/doi.org\/10.1038\/s41591-024-02989-6","journal-title":"Nat. Med."},{"issue":"26","key":"1127_CR18","doi-asserted-by":"publisher","first-page":"42076","DOI":"10.18632\/oncotarget.14942","volume":"8","author":"JM Xu","year":"2017","unstructured":"J.M. Xu, Y. Wang, Y.L. Chen, R. Jia, J. Li, J.F. Gong et al., Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget. 8(26), 42076\u201342086 (2017). https:\/\/doi.org\/10.18632\/oncotarget.14942","journal-title":"Oncotarget"},{"issue":"2","key":"1127_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"M. Katoh, H. Nakagama, FGF receptors: cancer biology and Therapeutics. Med. Res. Rev. 34(2), 280\u2013300 (2014). https:\/\/doi.org\/10.1002\/med.21288","journal-title":"Res. Rev."},{"issue":"4","key":"1127_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.21873\/cgp.20089","volume":"15","author":"D Shimizu","year":"2018","unstructured":"D. Shimizu, T. Saito, S. Ito, T. Masuda, J. Kurashige, Y. Kuroda et al., Overexpression of FGFR1 promotes peritoneal dissemination via epithelial-to-mesenchymal transition in gastric cancer. Cancer Genomics Proteom. 15(4), 313\u2013320 (2018). https:\/\/doi.org\/10.21873\/cgp.20089","journal-title":"Cancer Genomics Proteom."},{"issue":"8","key":"1127_CR21","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","volume":"119","author":"DA Hume","year":"2012","unstructured":"D.A. Hume, K.P.A. MacDonald, Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 119(8), 1810\u20131820 (2012). https:\/\/doi.org\/10.1182\/blood-2011-09-379214","journal-title":"Blood"},{"issue":"10","key":"1127_CR22","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"S.M. Pyonteck, L. Akkari, A.J. Schuhmacher, R.L. Bowman, L. Sevenich, D.F. Quail et al., CSF-1R Inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19(10), 1264\u20131272 (2013). https:\/\/doi.org\/10.1038\/nm.3337","journal-title":"Nat. Med."},{"key":"1127_CR23","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/S0959-8049(20)31132-1","volume":"138","author":"M Cheng","year":"2020","unstructured":"M. Cheng, S. Fan, R. Tang, W. Zhang, J. Hu, J. Yu et al., Evaluation of surufatinib, an orally available VEGFR, FGFR1 and CSF-1R inhibitor, in combination with immune checkpoint Blockade or chemotherapy in preclinical tumor models. Eur. J. Cancer. 138, S25 (2020). https:\/\/doi.org\/10.1016\/S0959-8049(20)31132-1","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"1127_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00262-024-03677-7","volume":"73","author":"P Zhang","year":"2024","unstructured":"P. Zhang, Z. Chen, S. Shi, Z. Li, F. Ye, L. Song et al., Efficacy and safety of Surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric\/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer. Cancer Immunol. Immunother. 73(7), 119 (2024). https:\/\/doi.org\/10.1007\/s00262-024-03677-7","journal-title":"Cancer Immunol. Immunother"},{"issue":"10142","key":"1127_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"K. Shitara, M. \u00d6zg\u00fcro\u011flu, Y.-J. Bang, M. Di Bartolomeo, M. Mandal\u00e0, M.-H. Ryu et al., Pembrolizumab versus Paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 392(10142), 123\u2013133 (2018). https:\/\/doi.org\/10.1016\/S0140-6736(18)31257-1","journal-title":"Lancet"},{"issue":"1","key":"1127_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1634\/theoncologist.2018-0142","volume":"24","author":"K Lee","year":"2019","unstructured":"K. Lee, C.H. Maeng, T. Kim, D.Y. Zang, Y.H. Kim, I.G. Hwang et al., A phase III study to compare the efficacy and safety of Paclitaxel versus Irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10\u201001). Oncologist. 24(1), 18\u2013e24 (2019). https:\/\/doi.org\/10.1634\/theoncologist.2018-0142","journal-title":"Oncologist"},{"issue":"4suppl","key":"1127_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1200\/JCO.2017.35.4_suppl.128","volume":"35","author":"R Xu","year":"2017","unstructured":"R. Xu, D. Zhang, L. Shen, J. Li, J. Huang, J. Gong et al., A phase I\/II trial of fruquintinib in combination with Paclitaxel for second-line treatment in patients with advanced gastric cancer. J. Clin. Oncol. 35(4suppl), 128\u2013128 (2017). https:\/\/doi.org\/10.1200\/JCO.2017.35.4_suppl.128","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"1127_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00001813-199804000-00003","volume":"9","author":"S Cascinu","year":"1998","unstructured":"S. Cascinu, F. Graziano, N. Cardarelli, M. Marcellini, P. Giordani, E.T. Menichetti et al., Phase II study of Paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 9(4), 307\u2013310 (1998). https:\/\/doi.org\/10.1097\/00001813-199804000-00003","journal-title":"Anticancer Drugs"},{"issue":"8","key":"1127_CR29","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1023\/A:1011680507956","volume":"12","author":"Y Yamada","year":"2001","unstructured":"Y. Yamada, K. Shirao, A. Ohtsu, N. Boku, I. Hyodo, H. Saitoh et al., Phase II trial of Paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against Paclitaxel-associated hypersensitivity reactions. Ann. Oncol. 12(8), 1133\u20131137 (2001). https:\/\/doi.org\/10.1023\/A:1011680507956","journal-title":"Ann. Oncol."},{"issue":"2","key":"1127_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s101200200015","volume":"5","author":"K Yamaguchi","year":"2002","unstructured":"K. Yamaguchi, M. Tada, N. Horikoshi, T. Otani, H. Takiuchi, S. Saitoh et al., Phase II study of Paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer. 5(2), 90\u201395 (2002). https:\/\/doi.org\/10.1007\/s101200200015","journal-title":"Gastric Cancer"},{"issue":"5","key":"1127_CR31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/annonc\/mdy055","volume":"29","author":"Y-K Kang","year":"2018","unstructured":"Y.-K. Kang, M.-H. Ryu, S.H. Park, J.G. Kim, J.W. Kim, S.-H. Cho et al., Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral Paclitaxel) versus i.v. Paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann. Oncol. 29(5), 1220\u20131226 (2018). https:\/\/doi.org\/10.1093\/annonc\/mdy055","journal-title":"Ann. Oncol."},{"issue":"12","key":"1127_CR32","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1002\/ijc.34894","volume":"154","author":"M Masetti","year":"2024","unstructured":"M. Masetti, S.-E. Al-Batran, T.O. Goetze, P. Thuss-Patience, J.R. Knorrenschild, E. Goekkurt et al., Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy. Int. J. Cancer. 154(12), 2142\u20132150 (2024). https:\/\/doi.org\/10.1002\/ijc.34894","journal-title":"Int. J. Cancer"},{"issue":"2","key":"1127_CR33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/ijc.33559","volume":"149","author":"LA Kankeu Fonkoua","year":"2021","unstructured":"L.A. Kankeu Fonkoua, S. Chakrabarti, M.B. Sonbol, P.M. Kasi, J.S. Starr, A.J. Liu et al., Outcomes on anti-VEGFR-2\/paclitaxel treatment after progression on immune checkpoint Inhibition in patients with metastatic gastroesophageal adenocarcinoma. Int. J. Cancer. 149(2), 378\u2013386 (2021). https:\/\/doi.org\/10.1002\/ijc.33559","journal-title":"Int. J. Cancer"},{"issue":"Suppl 2","key":"1127_CR34","doi-asserted-by":"publisher","first-page":"e000775","DOI":"10.1136\/esmoopen-2020-000775","volume":"4","author":"A Sasaki","year":"2020","unstructured":"A. Sasaki, A. Kawazoe, T. Eto, M. Okunaka, S. Mishima, K. Sawada et al., Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open. 4(Suppl 2), e000775 (2020). https:\/\/doi.org\/10.1136\/esmoopen-2020-000775","journal-title":"ESMO Open."},{"issue":"12","key":"1127_CR35","doi-asserted-by":"publisher","first-page":"e010041","DOI":"10.1136\/jitc-2024-010041","volume":"12","author":"Z Ji","year":"2024","unstructured":"Z. Ji, X. Wang, J. Xin, L. Ma, D. Zuo, H. Li et al., Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy. J. Immunother Cancer. 12(12), e010041 (2024). https:\/\/doi.org\/10.1136\/jitc-2024-010041","journal-title":"J. Immunother Cancer"},{"issue":"5","key":"1127_CR36","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s10120-020-01058-4","volume":"23","author":"A Sasaki","year":"2020","unstructured":"A. Sasaki, Y. Nakamura, Y. Togashi, H. Kuno, H. Hojo, S. Kageyama et al., Enhanced tumor response to radiotherapy after PD-1 Blockade in metastatic gastric cancer. Gastric Cancer Off J. Int. Gastric Cancer Assoc. Jpn Gastric Cancer Assoc. 23(5), 893\u2013903 (2020). https:\/\/doi.org\/10.1007\/s10120-020-01058-4","journal-title":"Gastric Cancer Off J. Int. Gastric Cancer Assoc. Jpn Gastric Cancer Assoc."},{"issue":"5","key":"1127_CR37","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s13402-024-00987-x","volume":"47","author":"C Huang","year":"2024","unstructured":"C. Huang, X. Wang, L. Wang, Y. Liu, Z. Xia, X. Wang et al., Targeting tumor associated macrophages (TAMs) reprograms tumor immune microenvironment to promote solid tumor immunotherapy. Cell. Oncol. 47(5), 2011\u20132014 (2024). https:\/\/doi.org\/10.1007\/s13402-024-00987-x","journal-title":"Cell. Oncol."},{"issue":"8","key":"1127_CR38","doi-asserted-by":"publisher","first-page":"e0182692","DOI":"10.1371\/journal.pone.0182692","volume":"12","author":"L Gu","year":"2017","unstructured":"L. Gu, M. Chen, D. Guo, H. Zhu, W. Zhang, J. Pan et al., PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLOS One. 12(8), e0182692 (2017). https:\/\/doi.org\/10.1371\/journal.pone.0182692","journal-title":"PLOS One"},{"key":"1127_CR39","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"X. Wang, F. Teng, L. Kong, J. Yu, PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther. 9, 5023\u20135039 (2016). https:\/\/doi.org\/10.2147\/OTT.S105862","journal-title":"OncoTargets Ther."},{"key":"1127_CR40","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2147\/DDDT.S75152","volume":"9","author":"Y Qing","year":"2015","unstructured":"Y. Qing, Q. Li, T. Ren, W. Xia, Y. Peng, G.-L. Liu et al., Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des. Devel Ther. 9, 901\u2013909 (2015). https:\/\/doi.org\/10.2147\/DDDT.S75152","journal-title":"Drug Des. Devel Ther."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01127-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-025-01127-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-025-01127-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:57:14Z","timestamp":1765443434000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-025-01127-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1127"],"URL":"https:\/\/doi.org\/10.1007\/s13402-025-01127-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6600621\/v1","asserted-by":"object"}]},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board and Ethics Committee (Approval letter No.: KY2022-151-B) of Renji Hospital, and was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and other applicable laws\/regulations of China. All participants provided written informed consent prior to screening.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}